Advancing Authentication: Next-Generation Technology for Cell Line and Model Authentication
According to multiple studies, one fifth to one third of popular cell lines have been contaminated by intraspecies/interspecies cell lines, mycoplasma and/or viruses.
Do you know that commonly used STR profiling assays may not be able to detect up to 15% cross-contamination in cell cultures?
In this webinar, Dr. Sheng Guo, Executive Director of Systems Biology, introduces the new Next-Generation Sequencing (NGS)-based SNP profiling assay for cell line and model authentication.
Watch this Webinar to Explore:
- Challenges in tracing, tracking and maintaining authenticity of cell line and tissue biosamples across different species
- Limitations of current STR and SNP assays, and how to overcome these limitations with our new NGS-based SNP profiling for cell line and model authentication
- How NGS-based SNP profiling can be used to detect contaminations with 1% sensitivity and 100% accuracy
- A cell line and model authentication service can be used for both human and mouse samples
- How contaminant in the bio sample can be identified and quantified
- Cost-effective solutions for detecting mycoplasma, viral, interspecies or intraspecies contamination, quantifying human-mouse mix ratio, inferring gender and genetic admixture pattern, and estimating cell line proportion in a mix of cell lines in a single assay
Who Should Watch:
- Directors, executives, operations officers, QC managers, researchers and principal investigators of pharmaceutical and biotech companies utilizing cell lines, xenografts and organoids in their drug development pipeline
- Academic and government researchers using cell lines and biosamples as model systems
- Biobank curators looking for high-throughput, ultra-sensitive technology to build and maintain high quality biobank
- Cell line authentication service providers looking for next-generation technology partnerships
About The Presenter:
Dr. Sheng Guo joined CrownBio in 2011 as the Executive Director, Systems Biology and also leads on all associated services. Prior to joining CrownBio, Sheng worked at Syngenta and Boehringer Ingelheim and has extensive expertise in tumor model genomics, preclinical statistics, predictive biomarker discovery, NGS-based product design, and industrial software development. Dr. Guo received his Ph.D. in Genomics and Computational Biology from the University of Pennsylvania, and B.Sc. in Biochemistry from Nankai University.